A vaccine to prevent Alzheimer's just got a regulatory boost. The FDA granted Fast Track designation to AV-1959R, an investigational amyloid-beta vaccine from Nuravax, targeting cognitively unimpaired adults who already have amyloid buildup in their brains. Phase 1 data showed all 12 vaccinated participants developed anti-amyloid antibodies, and a 160-person Phase 2 trial is expected to kick off in early 2027.
A vaccine to prevent Alzheimer's just got a regulatory boost
The FDA has granted Fast Track designation to AV-1959R, an investigational amyloid-beta vaccine developed by Nuravax, for the prevention of Alzheimer's disease in cognitively unimpaired adults with biomarker-confirmed amyloid pathology. This is a population where amyloid silently accumulates in the brain for up to two decades before any symptoms appear — and for whom no preventive therapy currently exists.
The designation was backed by Phase 1 data showing the vaccine was safe and well-tolerated, with strong immune responses. AV-1959R uses the MultiTEP platform, which generates antibodies that selectively target pathological forms of amyloid-beta — particularly protofibrils and fibrils — while largely sparing the harmless monomeric form. Fast Track status enables more frequent FDA interaction and could open the door to rolling review and Accelerated Approval down the line.
By the Numbers
Why it matters: Alzheimer's prevention has long been the holy grail of neurology. By targeting the disease in its silent, pre-symptomatic phase, AV-1959R represents a potentially paradigm-shifting approach — if it holds up in larger trials.
